[go: up one dir, main page]

SG10201803331PA - Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases - Google Patents

Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases

Info

Publication number
SG10201803331PA
SG10201803331PA SG10201803331PA SG10201803331PA SG10201803331PA SG 10201803331P A SG10201803331P A SG 10201803331PA SG 10201803331P A SG10201803331P A SG 10201803331PA SG 10201803331P A SG10201803331P A SG 10201803331PA SG 10201803331P A SG10201803331P A SG 10201803331PA
Authority
SG
Singapore
Prior art keywords
diseases
treatment
pyrrolo
pyrimidine derivatives
viral infections
Prior art date
Application number
SG10201803331PA
Inventor
Gowan David Craig Mc
Serge Maria Aloysius Pieters
Stefaan Julien Last
Werner EMBRECHTS
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of SG10201803331PA publication Critical patent/SG10201803331PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases 5 This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and /or therapy of diseases. No Figure Available. 10
SG10201803331PA 2013-06-27 2014-06-26 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases SG10201803331PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13174108 2013-06-27

Publications (1)

Publication Number Publication Date
SG10201803331PA true SG10201803331PA (en) 2018-06-28

Family

ID=48692351

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201510637UA SG11201510637UA (en) 2013-06-27 2014-06-26 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
SG10201803331PA SG10201803331PA (en) 2013-06-27 2014-06-26 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201510637UA SG11201510637UA (en) 2013-06-27 2014-06-26 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases

Country Status (25)

Country Link
US (2) US10385054B2 (en)
EP (1) EP3030563B1 (en)
JP (2) JP6763769B2 (en)
KR (1) KR102311234B1 (en)
CN (2) CN105473592B (en)
AU (2) AU2014301089B2 (en)
BR (1) BR112015032546B1 (en)
CA (1) CA2913028C (en)
CL (1) CL2015003686A1 (en)
DK (1) DK3030563T3 (en)
EA (2) EA202090258A3 (en)
ES (1) ES2645950T3 (en)
HR (1) HRP20171720T1 (en)
HU (1) HUE037125T2 (en)
IL (3) IL242655B (en)
MX (2) MX392130B (en)
MY (1) MY176142A (en)
NO (1) NO3030563T3 (en)
PH (1) PH12015502780B1 (en)
PL (1) PL3030563T3 (en)
PT (1) PT3030563T (en)
SG (2) SG11201510637UA (en)
SI (1) SI3030563T1 (en)
UA (1) UA117590C2 (en)
WO (1) WO2014207082A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3590928T (en) 2011-04-08 2021-08-25 Janssen Sciences Ireland Unlimited Company Pyrimidine derivatives for the treatment of viral infections
WO2014207082A1 (en) * 2013-06-27 2014-12-31 Janssen R&D Ireland Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
JOP20150177B1 (en) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv Compounds of 6, 7-dihydropyrazolo[1,5alpha]pyrazine-4(5H)-en and their use as negative Wisteria regulators of Melgor II receptors
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
PL3389727T3 (en) 2015-12-18 2021-02-08 Janssen Pharmaceutica Nv Radiolabelled mglur2/3 pet ligands
EP3389728B1 (en) 2015-12-18 2020-08-05 Janssen Pharmaceutica NV Radiolabelled mglur2/3 pet ligands
CA3027471A1 (en) * 2016-07-01 2018-01-04 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
KR102450287B1 (en) 2016-09-29 2022-09-30 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Pyrimidine prodrugs for treatment of viral infections and additional diseases
TW202415645A (en) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 2,4-diaminoquinazoline derivatives and medical uses thereof
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
JP7287708B2 (en) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like receptor 7 or 8 agonist-cholesterol conjugate and use thereof
JP2023512207A (en) 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー 1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists
JP7712941B2 (en) 2020-01-27 2025-07-24 ブリストル－マイヤーズ スクイブ カンパニー 1H-Pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists
EP4097105A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
WO2021154663A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115135655B (en) 2020-01-27 2024-07-02 百时美施贵宝公司 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists
CN115151546A (en) 2020-01-27 2022-10-04 百时美施贵宝公司 C3-substituted 1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists
CN115643805B (en) 2020-01-27 2024-11-08 百时美施贵宝公司 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists
WO2021154669A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097100A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
JP2023516372A (en) 2020-03-02 2023-04-19 プロジェニア インコーポレイテッド Biopathogen-mimicking nanoparticles based on pathogen outer wall components and method for producing the same
WO2022031057A1 (en) 2020-08-04 2022-02-10 성균관대학교산학협력단 Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2610889B2 (en) 1987-09-03 1997-05-14 日本臓器製薬株式会社 New crosslinked adenine derivatives
ATE283855T1 (en) 1996-07-03 2004-12-15 Sumitomo Pharma NEW PURINE DERIVATIVES
CZ68199A3 (en) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-heterobicyclic derivatives, pharmaceutical composition based thereon and method of treating diseases
EP0989129B1 (en) 1996-10-04 2002-12-11 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof
AR012634A1 (en) 1997-05-02 2000-11-08 Sugen Inc QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
US6329381B1 (en) 1997-11-28 2001-12-11 Sumitomo Pharmaceuticals Company, Limited Heterocyclic compounds
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO1999041253A1 (en) 1998-02-17 1999-08-19 Tularik Inc. Anti-viral pyrimidine derivatives
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP4342007B2 (en) 1998-08-10 2009-10-14 大日本住友製薬株式会社 Quinazoline derivatives
JP4315300B2 (en) 1998-08-10 2009-08-19 大日本住友製薬株式会社 Novel quinazoline derivatives
DE69917469T2 (en) 1998-08-27 2005-05-12 Sumitomo Pharmaceuticals Co., Ltd. PYRIMIDINE DERIVATIVES
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
AU2003271064B2 (en) 2002-09-27 2010-06-17 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound and use thereof
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
BRPI0411514A (en) 2003-06-20 2006-08-01 Coley Pharm Gmbh small molecule toll-like receptor antagonists
NZ545536A (en) 2003-09-05 2010-04-30 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C
TWI414525B (en) 2004-03-26 2013-11-11 Dainippon Sumitomo Pharma Co 9-substituted-8-oxoadenine compound
US20070225303A1 (en) 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
ES2442857T3 (en) 2004-08-10 2014-02-13 Janssen Pharmaceutica Nv 1,2,4-Triazin-6-one HIV inhibitor derivatives
BRPI0517559A (en) 2004-11-09 2008-10-14 Hoffmann La Roche compound, process for its preparation, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by ptb-1b inhibitors and use of the compounds
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
WO2006122003A2 (en) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
AR054122A1 (en) 2005-05-12 2007-06-06 Tibotec Pharm Ltd PIRIDO [2,3-D] USEFUL PYRIMIDES AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION OF THE SAME
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
JP4850911B2 (en) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Diaminopyrimidines as P2X3 and P2X2 / 3 modulators
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co Novel adenine compound
WO2007056208A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
MX2008010611A (en) 2006-02-17 2008-11-12 Pfizer Ltd 3 -deazapurine derivatives as tlr7 modulators.
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
KR101507182B1 (en) 2006-12-07 2015-03-30 제넨테크, 인크. Phosphoinositide 3-kinase inhibitor compounds and methods of use thereof
CN103224506A (en) 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 Antiviral indoles
EP2510946B1 (en) 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
JP2008222557A (en) * 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk PYRROLO[3,2-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS EFFECTIVE COMPONENT
DK2132209T3 (en) 2007-03-19 2014-04-14 Astrazeneca Ab 9-SUBSTITUTED 8-OXO ADENINE COMPOUNDS AS MODULATORS OF TLR7 (TOLL-LIKE RECEPTOR 7)
PE20081887A1 (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
WO2008147697A1 (en) 2007-05-22 2008-12-04 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
EA021463B1 (en) 2007-06-29 2015-06-30 Джилид Сайэнс, Инк. Purine derivatives and their use as modulators of toll-like receptor 7
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
CA2696824A1 (en) 2007-08-28 2009-03-12 Irm Llc Compounds and compositions as kinase inhibitors
WO2009030998A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Pyrimidine compounds as toll-like receptor (tlr) agonists
PE20091236A1 (en) * 2007-11-22 2009-09-16 Astrazeneca Ab PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
PL2238142T3 (en) 2007-12-24 2012-11-30 Janssen R&D Ireland Macrocyclic indoles as hepatitis c virus inhibitors
WO2009099650A2 (en) 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
CA2720850A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2009157560A1 (en) 2008-06-27 2009-12-30 京セラ株式会社 User interface generation device
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
UY31982A (en) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
EA201101650A1 (en) 2009-05-21 2012-07-30 Астразенека Аб NEW PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF MALIGNANT NONFORMS AND THE FOLLOWING DISEASES
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (en) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 Compounds for the reduction of β-amyloid production
WO2011049988A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
WO2011049825A1 (en) 2009-10-22 2011-04-28 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
KR101094446B1 (en) 2009-11-19 2011-12-15 한국과학기술연구원 2,4,7-substituted thieno [3,2-d] pyrimidine compounds with protein kinase inhibitory activity
JP2013032290A (en) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd Novel fused pyrimidine derivative
DE102010040233A1 (en) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclic aza heterocycles and their use
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
LT3590928T (en) 2011-04-08 2021-08-25 Janssen Sciences Ireland Unlimited Company Pyrimidine derivatives for the treatment of viral infections
US8916575B2 (en) 2011-05-18 2014-12-23 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
EA036645B1 (en) 2011-11-09 2020-12-03 Янссен Сайенсиз Айрлэнд Юси Purine derivatives for the treatment of viral infections
BR112014019699B1 (en) 2012-02-08 2021-12-07 Janssen Sciences Ireland Uc PIPERIDINO-PYRIMIDINE DERIVATIVES, THEIR USE IN THE TREATMENT OF VIRAL INFECTIONS AND THE PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM
RS61664B1 (en) 2012-04-24 2021-04-29 Vertex Pharma Dna-pk inhibitors
PL2872515T3 (en) 2012-07-13 2017-05-31 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
BR112015002524B1 (en) 2012-08-10 2021-11-03 Janssen Sciences Ireland Uc ALKYLPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITION INCLUDING THEM AND THE USE OF THE SAME
EP2712866A1 (en) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-triazine derivatives for the treatment of viral infections
CA2882786C (en) 2012-10-05 2020-10-20 Janssen Sciences Ireland Uc Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases.
SI2906563T1 (en) * 2012-10-10 2018-06-29 Janssen Sciences Ireland Uc Pyrrolo(3,2-d)pyrimidine derivatives for the treatment of viral infections and other diseases
MY171115A (en) 2012-11-16 2019-09-26 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
UA118751C2 (en) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі 2-aminopyrimidine derivatives for the treatment of viral infections
PL2978429T3 (en) 2013-03-29 2017-08-31 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
WO2014207082A1 (en) * 2013-06-27 2014-12-31 Janssen R&D Ireland Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
ES2836881T3 (en) 2013-07-30 2021-06-28 Janssen Sciences Ireland Unlimited Co Derivatives of thieno [3,2-d] pyrimidines for the treatment of viral infections
WO2016007966A2 (en) 2014-07-11 2016-01-14 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase

Also Published As

Publication number Publication date
IL258253A (en) 2018-05-31
IL264402B (en) 2019-09-26
PH12015502780A1 (en) 2016-03-21
NO3030563T3 (en) 2018-01-06
PL3030563T3 (en) 2018-01-31
MY176142A (en) 2020-07-24
IL242655B (en) 2018-04-30
NZ714267A (en) 2021-06-25
CN109369643A (en) 2019-02-22
US10385054B2 (en) 2019-08-20
DK3030563T3 (en) 2017-11-20
US20160168150A1 (en) 2016-06-16
NZ754320A (en) 2021-07-30
MX2015017671A (en) 2016-03-03
PT3030563T (en) 2017-11-15
AU2014301089B2 (en) 2018-10-04
CN105473592B (en) 2018-10-26
EA034893B1 (en) 2020-04-02
ES2645950T3 (en) 2017-12-11
PH12015502780B1 (en) 2016-03-21
JP6763769B2 (en) 2020-09-30
HRP20171720T1 (en) 2017-12-29
HK1218116A1 (en) 2017-02-03
BR112015032546A2 (en) 2017-07-25
CN109369643B (en) 2021-05-18
KR20160026880A (en) 2016-03-09
SI3030563T1 (en) 2017-12-29
CA2913028A1 (en) 2014-12-31
SG11201510637UA (en) 2016-01-28
MX392130B (en) 2025-03-21
EP3030563B1 (en) 2017-08-09
EA202090258A2 (en) 2020-05-31
US20200002342A1 (en) 2020-01-02
WO2014207082A1 (en) 2014-12-31
AU2018274911A1 (en) 2019-01-03
UA117590C2 (en) 2018-08-27
CA2913028C (en) 2022-03-08
BR112015032546B1 (en) 2022-05-17
EP3030563A1 (en) 2016-06-15
AU2018274911B2 (en) 2020-05-14
HUE037125T2 (en) 2018-08-28
IL258253B (en) 2019-02-28
CN105473592A (en) 2016-04-06
MX361527B (en) 2018-12-07
CL2015003686A1 (en) 2016-08-19
AU2014301089A1 (en) 2015-12-03
EA201690093A1 (en) 2016-04-29
IL264402A (en) 2019-02-28
JP2016526550A (en) 2016-09-05
EA202090258A3 (en) 2020-07-31
US10781216B2 (en) 2020-09-22
KR102311234B1 (en) 2021-10-12
JP2020203929A (en) 2020-12-24

Similar Documents

Publication Publication Date Title
PH12015502780B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2015004160A (en) 1,2,4-triazine derivatives for the treatment of viral infections.
PH12015502564A1 (en) Pyridone derivatives for the treatment of viral infections and further diseases